Every round on record, with the sources behind each and the investors on them.
A biotechnology startup originating from the University of Tokyo and the University of Tsukuba, with proprietary technology for the selective ex vivo expansion of hematopoietic stem cells (HSCs)
celaidtx.comLinkedInBunkyo-ku, Tokyo, JapanBiotechFounded 202016 people
5 sources
Source 2 dates the republished release Oct. 5, but the company's PR Newswire release and dateline state Oct. 4; the company's release wins.
1 source
The headline and opening sentence combine JPY 555 million in financing with an approximately JPY 500 million grant; the financing overview specifies JPY 555 million, which is used here. No lead investor is stated.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The page also shows an update date of 2024-10-29; the company's posted date, 2024-10-31, is used for the announcement day.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source distinguishes the 460 million yen extension from the approximately 1.2 billion yen total raise, which includes earlier Series A funding and a NEDO grant.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B ext. Series B financing round | $2.5M ~JPY 3.42B (approximately USD 22.1M) financing total JPY 400 million (approximately USD 2.6 million) | 2026-10-04 | not stated | No recent discussion |
5 sources [ VERIFIED ] read against 2 of 5 sources Source 2 dates the republished release Oct. 5, but the company's PR Newswire release and dateline state Oct. 4; the company's release wins. | ||||
Celaid Therapeutics develops cell therapies and platform technology that selectively expand scarce human hematopoietic stem cells outside the body for patients with blood and genetic diseases and for research and biopharma partners.
| Series B Series B financing round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $3.7M JPY 2.52B (USD 17.14M) financing total JPY 555 million (USD 3.77 million) | 2025-10-07 | not stated | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source
The headline and opening sentence combine JPY 555 million in financing with an approximately JPY 500 million grant; the financing overview specifies JPY 555 million, which is used here. No lead investor is stated. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: prnewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria·[ AGENT ]company research by the Firecrawl agent | ||||
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $916K 1.1B yen financing total 140 million yen | 2024-10-31 | not stated | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The page also shows an update date of 2024-10-29; the company's posted date, 2024-10-31, is used for the announcement day. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: celaidtx.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria·[ AGENT ]company research by the Firecrawl agent | ||||
| Series A ext. Series A extension [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $3.0M ~1.2B yen financing total 460 million yen | 2024-05-08 | The University of Tokyo Edge Capital Partners, Osaka University Venture Capital | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The source distinguishes the 460 million yen extension from the approximately 1.2 billion yen total raise, which includes earlier Series A funding and a NEDO grant. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: celaidtx.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria·[ AGENT ]company research by the Firecrawl agent | ||||
Celaid is addressing the donor shortages, HLA mismatches and transplant complications that limit allogeneic hematopoietic stem-cell transplantation, with CLD-001 using expanded frozen cord-blood HSCs for severe pediatric non-malignant diseases. Its latest financing brought cumulative funding including grants to approximately JPY 3.42 billion and is supporting U.S. IND and clinical-trial preparation after positive animal data, an established manufacturing process, transfer to a U.S. CDMO and completion of an FDA Pre-IND meeting.
Checked against 10 sources today
Via Alexandria from FullEnrich: type, industry
Also named as backers in company research: Japan Agency for Medical Research and Development (AMED), AMED Strengthening Program for Pharmaceutical Startup Ecosystem